| | | | |
CUSIP No. 88025U109 | | 13G | | Page 4 of 9 Pages |
Item 1(a). | Name of Issuer: |
10x Genomics, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
6230 Stoneridge Mall Road
Pleasanton, California 94588
Item 2(a). | Name of Person Filing: |
This statement is being jointly filed by each of the entities below pursuant to Rule13d-1(k) promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Act, all of whom together are referred to herein as the “Reporting Persons”:
| (i) | SoftBank Vision Fund (AIV M2) L.P. |
| (ii) | SB Investment Advisers (UK) Limited |
The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2020, a copy of which is attached asExhibit 99.1 to this Schedule 13G, pursuant to which the Reporting Persons agreed to file this Schedule 13G and any amendments thereto jointly in accordance with the provisions of Rule13d-1(k)(1) under the Act.
Item 2(b). | Address of Principal Business Office or, if none, Residence: |
The principal business address of each of the Reporting Persons is as follows:
| (i) | SoftBank Vision Fund (AIV M2) L.P. |
251 Little Falls Drive
Wilmington, DE 19808
| (ii) | SB Investment Advisers (UK) Limited |
69 Grosvenor Street
London W1K 3JW
United Kingdom
See responses to Item 4 on each cover page.
Item 2(d). | Titles of Classes of Securities: |
Class A common stock, $0.00001 par value per share (the “Class A Common Stock”)
88025U109
Item 3. | If This Statement is Filed Pursuant to Rule13d-1(b), or13d-2(b) or (c), Check Whether the Person Filing is a(n): |
| | | | |
(a) | | ☐ | | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
| | |
(b) | | ☐ | | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |